Voiglim MV1

Voiglim MV1 by Voithea Healthcare is a powerful anti-diabetic combination of Glimepiride 1mg, Metformin 500mg, and Voglibose 0.2mg, specially formulated to manage type 2 diabetes with a multi-targeted approach. Glimepiride promotes insulin secretion, Metformin enhances insulin sensitivity and reduces hepatic glucose production, while Voglibose delays the absorption of carbohydrates from the intestine, preventing postprandial blood sugar spikes.

This triple-drug therapy is ideal for patients requiring comprehensive glycemic control, especially those struggling with elevated post-meal glucose levels. Voiglim MV1 offers a balanced and synergistic solution for diabetes management, supported by Voithea Healthcare’s dedication to delivering effective, safe, and affordable care.